Boston Scientific Corp. [BSX] stock prices are up 0.59% to $67.82 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The BSX shares have gain 2.43% over the last week, with a monthly amount glided 4.68%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 1, March 2024, Boston Scientific Receives FDA Approval for the AGENT™ Drug-Coated Balloon. In a post published today on Yahoo Finance, First coronary drug-coated balloon in U.S. provides safe, effective alternative to treat coronary in-stent restenosis and reduce risk of reoccurrence.
From an analyst’s perspective:
Boston Scientific Corp. [NYSE: BSX] stock has seen the most recent analyst activity on February 01, 2024, when Mizuho upgraded its rating to a Buy and also boosted its price target to $80 from $65. Previously, Robert W. Baird started tracking the stock with Outperform rating on July 19, 2023, and set its price target to $59. On June 30, 2023, CL King initiated with a Buy rating and assigned a price target of $64 on the stock. UBS initiated its recommendation with a Buy and recommended $57 as its price target on March 29, 2023. Mizuho started tracking with a Neutral rating for this stock on December 22, 2022, and assigned it a price target of $52.
The stock price of Boston Scientific Corp. [BSX] has been fluctuating between $46.20 and $67.67 over the past year. Currently, Wall Street analysts expect the stock to reach $57.93 within the next 12 months. Boston Scientific Corp. [NYSE: BSX] shares were valued at $67.82 at the most recent close of the market. An investor can expect a potential drop of -14.58% based on the average BSX price forecast.
Analyzing the BSX fundamentals
The Boston Scientific Corp. [NYSE:BSX] reported sales of 14.24B for trailing twelve months, representing a surge of 14.90%. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at 0.16%, Pretax Profit Margin comes in at 0.14%, and Net Profit Margin reading is 0.11%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.09 and Total Capital is 0.08. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.49.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 67.49 points at the first support level, and at 67.17 for the second support level. However, for the 1st resistance point, the stock is sitting at 68.07, and for the 2nd resistance point, it is at 68.33.
Boston Scientific Corp. [BSX] reported earnings per share of $0.55 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.51/share, meaning a difference of $0.04 and a surprise factor of 7.80%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.5 per share as compared to estimates of $0.48 per share, a difference of $0.02 representing a surprise of 4.20%.
Ratios To Look Out For
It’s worth pointing out that Boston Scientific Corp. [NYSE:BSX]’s Current Ratio is 1.32. On the other hand, the Quick Ratio is 0.82, and the Cash Ratio is 0.18. Considering the valuation of this stock, the price to sales ratio is 6.99, the price to book ratio is 5.16 and price to earnings (TTM) ratio is 63.37.
Transactions by insiders
Recent insider trading involved Carruthers Wendy, EVP, Human Resources, that happened on Mar 01 ’24 when 6983.0 shares were sold. EVP& Grp Pres, MedSurg & APAC, Butcher Arthur C completed a deal on Feb 26 ’24 to sell 9335.0 shares. Meanwhile, EVP, Human Resources Carruthers Wendy sold 6983.0 shares on Feb 23 ’24.
